Quote from: Twinkledoe on October 31, 2017, 10:48:41 PM

Quote from: imctoken on October 31, 2017, 07:50:11 AM

Quote from: Twinkledoe on October 31, 2017, 01:22:55 AM

Okay, the team comprises of real people based in Taiwan as your chief consultant can be found here - http://www.life.nctu.edu.tw/en/faculty/bioinfo.

So given the fact that you can provide us this service or these biomedical researches, how can you assure potential investors that this project will really gain profit as researches are known to be long-term projects and it will be years before they can even see the glimpse of the ROI of their investment? What if the project failed to produce such antibody drug prediction system for instance? What will happen next? Trying to be pessimistic here to expect the worst case scenario. This project will be years in the making.

Thank you for the comment.

Indeed, the research and development of antibody drug takes years,
even with the assistance of artificial intelligence prediction.
We cannot promise how much profit we will made.

However,
the ways the project earns money include not only antibody drugs (long-term),
but also selling products of our future partners (short-term)
and customized big data analysis and prediction services (middle-term).

We are now confident that, with sufficient fund, our key techniques will enable us to establish the first practical antibody-structure prediction system in ten years, for the fact that a prototype has been running in our server (evening the efficiency is low because of the shortage of computing power).

Okay thank you for answering. Since you mentioned your short-term services, may we know what products you are targeting to sell in the public? Of course, you should have already thought about partners for this venture as that might draw the attention of investors. You should at least provide some details on that. Otherwise, it's not attractive to some as most people are looking for short-term investments especially in crypto.

Thanks again for your reply and interest.

Short-term services may include personal gene sequencing to help customers know what risks of health they may have in the future,
such as the probabilies to grow breast cancer, colorectal cancer, etc. According to the results we may provide consultation services to help customers design suitable prevention methods (such as adjustment of lifestyle), or select food, nutritional supplements or treatments. We have partners running next-generation sequencing companies, importing/making nutritional supplements and doing organic agriculture. We are seeking for hospitals to be our partners as well. We know that these short-term benefits may not be huge (it's actually huge, but highly competitive).

If without ICO we may struggle for many more years by starting a company based on such small benefits because the insufficiency of resources restricts the progress of the antibody drug design system we are developing. This is why we launch the IMC ICO project, which may bring us plenty of resources to accelerate our develop and shorten the short-term and middle-term periods.